BACKGROUND: The burden of @entity65 is predicted to escalate in developing countries. While many studies have reported the descriptive epidemiology, practice patterns and outcomes of @entity1 hospitalised with @entity1187 ( @entity1187 ), these have largely been confined to the developed nations. METHODS: In this prospective, observational registry, 12 068 adults hospitalised with a diagnosis of @entity1187 were enrolled between January 2007 and January 2008 at 134 sites in 19 countries in Africa, Latin America and the Middle East. Data on @entity1 characteristics, treatment and outcomes were collected. RESULTS: Of the 642 @entity1 from South Africa in the registry, 615 had a confirmed @entity1187 diagnosis and form the basis of this report; 41% had a discharge diagnosis of @entity583 ( @entity583 ) and 59% a diagnosis of non-ST-segment elevation @entity1187 (NSTE- @entity1187 ), including 32% with non- @entity583 (NSTEMI) and 27% with @entity1459 ( @entity1459 ). During hospitalisation, most @entity1 received @entity117 (94%) and a lipid-lowering medication (91%); 69% received a beta-blocker, and 66% an @entity1289 inhibitor/angiotensin receptor blocker. Thrombolytic therapy was used in only 18% of subjects (36% of @entity583 @entity1 and 5.5% of NSTE- @entity1187 @entity1 ). Angiography was undertaken in 93% of @entity1 (61.3% on the first day), of whom 53% had a percutaneous coronary intervention (PCI) and 14% were referred for coronary artery bypass surgery. Drug-eluting stents were used in 57.9% of cases. @entity1397 was prescribed at discharge from hospital in 62.2% of @entity1 . All-cause @entity204 at 12 months was 5.7%, and was higher in @entity1 with @entity583 versus non-ST-elevation @entity1187 (6.7 vs 5.0%, p < 0.0001). Clinical factors associated with higher risk of @entity204 at 12 months included age >=  70 years, presence of @entity6 on admission, and a history of @entity64 ( @entity64 ). CONCLUSIONS: In this observational study of @entity1187 @entity1 , the use of evidence-based pharmacological therapies for @entity1187 was quite high. Interventional rates were high compared to international standards, and in particular the use of drug-eluting stents, yet the clinical outcomes (mortality, re-admission rates and severe @entity548 episodes at one year) were favourable, with low rates compared with other studies.

Management of XXXX in South Africa: insights from the ACCESS (Acute Coronary Events - a Multinational Survey of Current Management Strategies) registry.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome', 'acute coronary syndromes'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke/transient ischaemic attack', 'TIA'] @entity1289 :: ('1636', 'Gene') :: ['ACE'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['Clopidogrel'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1459 :: ('MESH:D000789', 'Disease') :: ['UA', 'unstable angina'] @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'ST-segment elevation myocardial infarction'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']
@entity1187 :: (MESH:D054058,Disease) :: ['acute coronary syndrome']
